Ectonucleoside triphosphate diphosphohydrolase 6 expression in testis and testicular cancer and its implication in cisplatin resistance

Oncology Reports

Volumn 26, Issue 1, 2011, Pages 161-167

  Tada, Yasuhiro ^a   Yokomizo, Akira ^a   Shiota, Masaki ^a   Song, Yoohyun ^a   Kashiwagi, Eiji ^a   Kuroiwa, Kentaro ^a   Oda, Yoshinao ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cisplatin; E cadherin; Ectonucleoside triphosphate diphosphohydrolase 6; Testicular cancer; Testis

Indexed keywords

APYRASE; BIOLOGICAL MARKER; CISPLATIN; COMPLEMENTARY DNA; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 6; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENTPD6 ONCOGENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; ORCHIECTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMINOMA; TESTIS CANCER; TESTIS TUMOR; UPREGULATION;

ANTINEOPLASTIC AGENTS; CADHERINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYROPHOSPHATASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TESTICULAR NEOPLASMS; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955857909     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1274     Document Type: Article

References (35)

1. Garner MJ, Turner MC, Ghadirian P and Krewski D: Epidemiology of testicular cancer: an overview. Int J Cancer 116: 331-339, 2005. (Pubitemid 40993328)
2. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435-1440, 1987. (Pubitemid 17079090)
3. Feldman DR, Bosl GJ, Sheinfeld J and Motzer RJ: Medical treatment of advanced testicular cancer. JAMA 299: 672-684, 2008. (Pubitemid 351252727)
4. Zimmermann H: Ectonucleotidases: some developments and a note on nomenclature. Drug Develop Res 52: 44-56, 2001.
5. Robson S, Sévigny J and Zimmermann H: The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2: 409-430, 2006.
6. Bigonnesse F, Levesque SA, Kukulski F, et al: Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. Biochemistry 43: 5511-5519, 2004 (Pubitemid 38620943)
7. Burnstock G: Dual control of local blood flow by purines. Ann N Y Acad Sci 603: 31-44, 1990.
8. Kunapuli SP and Daniel JL: P2 receptor subtypes in the cardiovascular system. Biochem J 336: 513-523, 1998. (Pubitemid 29008006)
9. Ralevic V and Burnstock G: Involvement of purinergic signalling in cardiovascular diseases. Drug News Perspect 16: 133-140, 2003. (Pubitemid 37314098)
10. Wang TF and Guidotti G: Golgi localization and functional expression of human uridine diphosphatase. J Biol Chem 273: 11392-11399, 1998.
11. Biederbick A, Kosan C, Kunz J and Elsasserm H: First apyrase splice variants have different enzymatic properties. J Biol Chem 275: 19018-19024, 2000. (Pubitemid 30422868)
12. Mulero JJ, Yeung G, Nelken ST and Ford JE: CD39-L4 is a secreted human apyrases, specific for the hydrolysis of diphosphates. J Biol Chem 274: 20064-20067, 1999.
13. Yamamoto T, Komatsubara S, Suzuki T and Oboshi S: In vitro cultivation of human testicular embryonic carcinoma and establishment of new cell line. Gann 70: 677-680, 1979.
14. Kotoh S, Naito S, Yokomizo A, et al: Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 54: 3248-3252, 1994. (Pubitemid 24208937)
15. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M and Kumazawa J: Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 157: 1054-1058, 1997. (Pubitemid 27066316)
16. Shiota M, Yokomizo A, Tada Y, et al: P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci 101: 1797-1806, 2010.
17. Shiota M, Yokomizo A, Kashiwagi E, et al: Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101: 1177-1185, 2010.
18. Tsunoda T, Koga H, Yokomizo A, et al: Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 24: 1396-1402, 2005. (Pubitemid 40343119)
19. Tada Y, Wada M, Kuroiwa K, et al: MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6: 4618-4627, 2000. (Pubitemid 32110396)
20. Shiota M, Yokomizo A, Tada Y, et al: Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29: 237-250, 2010.
21. Song Y, Oda Y, Hori M, et al: N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin. Hum Pathol 41: 214-222, 2010.
22. Shiota M, Yokomizo A, Tada Y, et al: Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol 24: 114-127, 2010.
23. Koppikar P, Lui VW, Man D, et al: Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 14: 7682-7690, 2008.
24. Arumugam T, Ramachandran V, Fournier KF, et al: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828, 2009.
25. Braun N, Fengler S, Ebeling C, Servos J and Zimmermann H: Sequencing, functional expression and characterization of rat NTPDase6, a nucleoside diphosphatase and novel member of the ecto-nucleoside triphosphate diphosphohydrolase family. Biochem J 351: 639-647, 2000.
26. Naito S, Yokomizo A and Koga H: Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol 6: 427-439, 1999. (Pubitemid 29425476)
27. Naito S, Koga H, Yokomizo A, et al: Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J Surg 24: 1183-1186, 2000.
28. Shiota M, Izumi H, Onitsuka T, et al: Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68: 98-105, 2008. (Pubitemid 351380110)
29. Shiota M, Izumi H, Tammoto A, et al: Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 69: 3148-3156, 2009.
30. Zhou WL, Wang Y, Zhou XL, Zhang YS and Chen ZT: Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun 369: 1098-1102, 2008.
31. Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166, 2009.
32. Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193, 1998. (Pubitemid 28162793)
33. Kuroiwa K, Konomoto T, Kumazawa J, Naito S and Tsuneyoshi M: Cell proliferative activity and expression of cell-cell adhesion factors (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) in sarcomatoid renal cell carcinoma. J Surg Oncol 77: 123-131, 2001. (Pubitemid 32520774)
34. Migita T, Oda Y, Masuda K, et al: Inverse relationship between E-cadherin and p27Kip1 expression in renal cell carcinoma. Int J Oncol 33: 41-47, 2008.
35. Tada Y, Wada M, Taguchi K, et al: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62: 4048-4053, 2002. (Pubitemid 34791073)